Journal of clinical gastroenterology · 2026
Metabolic Syndrome Is Associated With Worsened Clinical Outcomes in Individuals With Necrotizing Pancreatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
AbiMansour Jad P, Jagannath Preethi, Nwankwo Eugene, Garg Sushil, Han Samuel, Vege Santhi S, Ashkar Motaz H, Kassmeyer Blake, Chandrasekhara Vinay
Аннотация
GOALS: Evaluate the relationship between metabolic syndrome (MetS) and clinical outcomes in individuals with necrotizing pancreatitis (NP) and infected pancreatic necrosis (IPN).
BACKGROUND: MetS affects a significant proportion of the global population and is associated with low-grade systemic inflammation and immune dysregulation. This has implications for several disease processes, but the impact of MetS on patients with NP is not well characterized.
STUDY: A retrospective cohort study of patients admitted with NP at a single tertiary center was performed. MetS was defined as meeting any 3 of the following criteria: BMI ≥30 kg/m2, triglycerides ≥150 mg/dL, fasting glucose ≥110 mg/dL, blood pressure ≥130/85 mm Hg, and low HDL (<40 mg/dL men, <50 mg/dL women). The need for intensive care, hospital length of stay, development of organ failure, and mortality were compared in patients with NP with or without MetS. Secondary outcomes included the incidence of IPN.
RESULTS: A total of 276 (154 MetS, 55.8%) patients were identified. Individuals with MetS more frequently required ICU-level care (38.3% vs. 17.2%; P<0.001) and longer length of stay (9.0 vs. 5.0 d; P=0.029). There was a higher risk of sepsis in those with MetS (27.5% vs. 15.6%; P=0.019), as well as respiratory failure (31.2% vs. 18%; P=0.013), renal failure (35.7% vs. 21.3%; P=0.009), and in-hospital mortality (17.5% vs. 8.2%; P=0.024). The incidence of IPN was higher in patients with MetS (39.6% vs. 23.0%; P=0.003).
CONCLUSION: The presence of MetS in individuals with NP was associated with worsened outcomes, including increased incidence of IPN, sepsis, organ failure, ICU admission, and mortality during index hospitalization.
BACKGROUND: MetS affects a significant proportion of the global population and is associated with low-grade systemic inflammation and immune dysregulation. This has implications for several disease processes, but the impact of MetS on patients with NP is not well characterized.
STUDY: A retrospective cohort study of patients admitted with NP at a single tertiary center was performed. MetS was defined as meeting any 3 of the following criteria: BMI ≥30 kg/m2, triglycerides ≥150 mg/dL, fasting glucose ≥110 mg/dL, blood pressure ≥130/85 mm Hg, and low HDL (<40 mg/dL men, <50 mg/dL women). The need for intensive care, hospital length of stay, development of organ failure, and mortality were compared in patients with NP with or without MetS. Secondary outcomes included the incidence of IPN.
RESULTS: A total of 276 (154 MetS, 55.8%) patients were identified. Individuals with MetS more frequently required ICU-level care (38.3% vs. 17.2%; P<0.001) and longer length of stay (9.0 vs. 5.0 d; P=0.029). There was a higher risk of sepsis in those with MetS (27.5% vs. 15.6%; P=0.019), as well as respiratory failure (31.2% vs. 18%; P=0.013), renal failure (35.7% vs. 21.3%; P=0.009), and in-hospital mortality (17.5% vs. 8.2%; P=0.024). The incidence of IPN was higher in patients with MetS (39.6% vs. 23.0%; P=0.003).
CONCLUSION: The presence of MetS in individuals with NP was associated with worsened outcomes, including increased incidence of IPN, sepsis, organ failure, ICU admission, and mortality during index hospitalization.